Ana-Matea Mikecin Dražić

Ana-Matea Mikecin Dražić

Auto-generated profile, based on publicly available information

Ana-Matea Mikecin Dražić

Ruđer Bošković Institute 1 Division of Molecular Medicine Bijenička c. 54, 10000 Zagreb , Croatia

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2023 in Journal of Cell Science
Verified
Journal Article
Closed access
PDF file
MMMarko Marjanović
Marko Marjanović
ADAna-Matea Mikecin Dražić
Ana-Matea Mikecin Dražić
MMMarija Mioc
Marija Mioc
MPMladen Paradzik
Mladen Paradzik
FKFilip Kliček
Filip Kliček
MKMarijeta Kralj
Marijeta Kralj
Epithelial-to-mesenchymal transition (EMT) gives rise to cells with properties similar to cancer stem cells (CSCs). Targeting the EMT program to selectively eliminate CSCs is a promising way to improve cancer therapy. Salinomycin (Sal), a K+/H+ ionophore, was identified as highly selective towards CSC-like cells, but its mechanism of action and selectivity remains elusive. Here, we show that Sal, similar to monensin and nigericin, disturbs the function of the Golgi. Sal alters the expression of Golgi-related genes and leads to marked changes in Golgi morphology, particularly in cells that have undergone EMT. Moreover, Golgi-disturbing agents severely affect post-translational modifications of proteins, including protein processing, glycosylation and secretion. We discover that the alterations induced by Golgi-disturbing agents specifically affect the viability of EMT cells. Collectively, our work reveals a novel vulnerability related to the EMT, suggesting an important role for the Golgi in the EMT and that targeting the Golgi could represent a novel therapeutic approach against CSCs.